made

Moonbeam, Diode Collaborate on Launch of DePIN Platform to Replace Traditional VPN, Web2 Products

Diode chooses Moonbeam to deploy suite of blockchain solutions that align with Polkadot founder Gavin Woods’ original vision for Web3 [SINGAPORE] – Moonbeam Network, a smart contract platform for building cross-chain connected applications, today announced the launch of Diode’s secure and decentralized communications platform. Diode’s solution is part of a movement known as DePIN, or “decentralized physical infrastructure network,” where blockchain protocols operate real-world infrastructure in a decentralized manner. Providing a censorship-resistant alternative to traditional products like VPN, Slack or Microsoft OneDrive, Diode’s massively scalable platform helps to bring about

Paribus Embracing DAO transition.

In our journey of developing Paribus, we’ve received a lot of feedback from our community, primarily positive and helpful. But, as is often the case when a small team controls a platform, not everyone agrees with our decisions. At every step, we’ve tried to make the best choices based on the information we had. We’ve always known that, eventually, it would be the community’s turn to take the lead in guiding Paribus. And, as we announced in our recent X-space update, that time is approaching fast with the release of

Skale x Cryptopia Making Free-to-play-and-earn A Reality For Gamers

Nov 21, 2023. Tortola, British Virgin Islands. With great excitement, we are pleased to announce our partnership with Skale, a zero-gas fee EVM blockchain. As a pioneering free-to-play-and-earn game that embodies the spirit of a new era in gaming, this alliance is set to transform the gaming landscape by empowering players to combine fun and earning opportunities without the constraints of excessive fees or financial barriers. We are living in exciting times. Gradually, we are entering an era where games are not only for fun but also offer a seamless

NKGEN Biotech Received FDA Approval for Clinical Trials of SKN01 NK Cell Therapy in Alzheimer’s Disease Treatment.

Summary: Progress in Neurodegenerative Research:  NKGen’s Phase 1/2a Clinical Trial for SNK01 on Track for End-of-Year Initiation SANTA ANA, Calif., Oct. 24, 2023 (Plato / Amplifi) -- Today, NKGen Biotech Inc. (Nasdaq: NKGN), a trailblazer in the field of autologous, allogeneic, and CAR-NK natural killer cell therapeutics, proudly announced the progression of its SNK01 program targeting Alzheimer’s Disease (AD), backed by the green light from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application. NKGen is gearing up to initiate its Phase 1/2a clinical trial

K10 Esports Embarks on a Revolutionary Journey: From Championships to the TCG World Metaverse.

An Exciting New Frontier for Esports Fans and Gamers Alike London, England. October 6, 2023. In a groundbreaking move that promises to redefine the esports landscape, the globally-renowned K10 Esports announces its next venture: diving into the world of the Metaverse with TCG World. As they continue their relentless pursuit of glory in games such as CS2, Valorant, and many more titles to come, K10 is now set to offer fans an unprecedented immersive experience by streaming their matches live in virtual venues within the TCG World Metaverse. This pioneering

Blockpass integrates award-winning ID system with Solana Wallets, offers special discount to Solana projects

HONG KONG, Sept 7, 2023 - (ACN Newswire) - Blockpass has announced that it will be integrating its identity verification solution with Solana Wallets and supporting Solana projects with its revolutionary On-Chain KYC(R) solution. Additionally, Blockpass will provide a unique special offer available to all Solana projects in the form of a 50% discount. Solana is a blockchain network with the fundamental ideals of an open-source community, decentralization, staking and censorship resistance at its heart. The Solana network is validated by thousands of independently-operating nodes that ensures data remains secure

Gain Therapeutics Achieves Remarkable Breakthrough in Parkinson’s Disease Research

Gain Therapeutics, Inc. (Nasdaq: GANX), a pioneering biotechnology company specializing in innovative allosteric small molecule therapies, has made significant strides in the fight against Parkinson's disease (PD). The Company's lead drug candidate, GT-02287, has demonstrated extraordinary potential in mitigating the effects of Parkinson's disease across two distinct preclinical models of the ailment. These findings suggest that GT-02287 has the capacity to alleviate Parkinson's disease pathology and enhance motor function. A notable highlight is the substantial reduction of plasma Neurofilament Light Chain (NfL) levels, an emerging biomarker for neurodegeneration. This advancement

JBL Quantum TWS Air Review: Sometimes less is more

The JBL Quantum TWS Air headphones have improved sound quality over the previous model and are perfect for low-latency gaming with the included USB-C dongle. The redesigned headphones have a lightweight and comfortable fit, but some users may experience issues operating the overly sensitive touch buttons. The headphones offer solid connectivity with Bluetooth 5.3 and an included USB-C dongle, and have a good battery life of up to 24 hours. In 2022, JBL launched the Quantum TWS headphones. They were pretty average except for a USB-C dongle which made them

Coya Therapeutics Reports Additional Biomarker and Imaging Data Showing Decrease in Neuroinflammation with COYA 301 in Alzheimer’s Disease.

Highlights Coya reports new data illustrating that administration of COYA 301 (low dose Interleukin-2 (IL-2)) in an open- label study in 8 patients with mild to moderate AD (COYA 301 Trial) resulted in a statistically significant reduction in the expression of three well characterized proinflammatory cytokines -- Tumor Necrosis Factor alpha (TNF-α), Interleukin 6 (IL-6), and Interleukin 1- Beta (IL-1β) -- which correlated with lack of cognitive decline of the patients over the course of the study. TNF-α is one of the main inflammatory cytokines involved in initiating and propagating